Testing P2Y12 platelet inhibitors generics beyond bioequivalence: a parallel single-blinded randomized trial

Thrombosis Journal

Table 4 Comparison on incidence of side effects developed in Brili versus Tica groups during the study period

Parameter	Brili group-brand (N = 14)	Tica group-generic (N = 15)	p-value
No of males (%)	3 (21.4%)	5 (33.3%)	0.682^¥
New-onset dyspnea (%)	2 (14.2%)	0	0.224^¥
Rash (%)	1 (7.1%)	2 (13.3%)	0.999^¥
Hb (10⁶cell/μL)	12 (9.2–15.4)	12 (9.6–15.1)	0.982^#
PLT (10³cell/μL)	315 (172–405)	303 (181–484)	0.836^#

Data are presented as median (range) for continuous variables and frequency (percentage) for categorical variables
Abbreviation: Brili Brilique®, Tica Ticaloguard®, Hb Hemoglobin, PLT Platelet count, P#: Non-significant by independent-sample Mann–Whitney U test; P¥: Non-significant by Fisher’s Exact test

ISSN: 1477-9560